Ballentine Partners’s Arcutis Biotherapeutics ARQT Stock Holding History

Ballentine Partners’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$268K	Sell	10,230 -354	-3%	-$8.25K	﹤0.01%	853
2026 Q1	$249K	Hold	10,584	–	–	﹤0.01%	823
2025 Q4	$307K	Buy	+10,584	New	+$271K	﹤0.01%	714
2023 Q4	–	Sell	-10,386	Closed	-$55.1K	–	688
2023 Q3	$55.1K	Buy	10,386 +281	+3%	+$2.39K	﹤0.01%	594
2023 Q2	$96.3K	Sell	10,105 -88	-0.9%	-$977	﹤0.01%	583
2023 Q1	$112K	Buy	+10,193	New	+$147K	﹤0.01%	543
2021 Q3	–	Sell	-7,377	Closed	-$201K	–	422
2021 Q2	$201K	Buy	+7,377	New	+$208K	0.01%	401

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Ballentine Partners's ARQT Position: Q2 2026 in Review

Ballentine Partners reduced its Arcutis Biotherapeutics (ARQT) stake by 3.3% in Q2 2026, selling an estimated $8.25K and leaving 10,230 shares worth $268K. The position accounts for ﹤0.01% of the portfolio, ranked #853.

Ballentine Partners first reported a position in ARQT in Q2 2021 and has held it in 7 quarters since. The position peaked at $307K in Q4 2025. 273 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

Ballentine Partners held 10,230 shares of Arcutis Biotherapeutics worth $268K as of Q2 2026.
Ballentine Partners sold 354 Arcutis Biotherapeutics shares in Q2 2026, an estimated $8.25K.
Arcutis Biotherapeutics made up ﹤0.01% of Ballentine Partners's portfolio in Q2 2026, its #853 holding.
Ballentine Partners first reported a position in Arcutis Biotherapeutics in Q2 2021 and has held it in 7 quarters since.
Ballentine Partners's Arcutis Biotherapeutics position peaked at $307K in Q4 2025.
273 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Ballentine Partners's 13F filing for Q2 2026, filed 17 Jul 2026.